Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma (SOPT)
NCT05117957Phase 2Completed
- Start
- Mar 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in hepatocellular carcinoma (HCC). Primary endpoints: Progression-free survival at 12 months and Adverse events at 12 months. Started Mar 2022; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05117957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117957.